ATS (American Thoracic Society) International Conference 2024
ATS 2024 showcases the latest advances and discoveries in respiratory science, patient care and global respiratory health. At a unique moment in history, these breakthroughs will shape our future as scientists, healthcare professionals and leaders in the field.
Stop by the Clario Booth #2935 to talk to our experts and find out what’s new in tools, training, and support you need to tackle respiratory endpoints for your trials.
Session Information:
Thematic Poster Session A38: HIGHLIGHTS OF BEHAVIORAL SCIENCE AND HEALTH SERVICES RESEARCH
Date: Sunday, May 19, 2024
Time: 11:30 a.m. – 1:15 p.m.
Poster Title: Clinical Evaluation of Artificial Intelligence Supported Software in the Interpretation of Spirometry Results in a Primary Care Setting
Authors:
- Julie Maes – Product Manager at ArtiQ
Thematic Poster Session A38: HIGHLIGHTS OF BEHAVIORAL SCIENCE AND HEALTH SERVICES RESEARCH
Date: Sunday, May 19, 2024
Time: 11:30 a.m. – 1:15 p.m.
Poster Title: High-quality FVC Through Automated AI-based Detection of Early Termination in Spirometry: A Comparative Analysis
Authors:
- Benoit Cuyvers – Product Manager at ArtiQ
- Marko Topalović, Ph.D. – CEO at ArtiQ
Thematic Poster Session A38: HIGHLIGHTS OF BEHAVIORAL SCIENCE AND HEALTH SERVICES RESEARCH
Date: Sunday, May 19, 2024
Time: 11:30 a.m. – 1:15 p.m.
Poster Title: Is Onsite Spirometry Quality Predicting the Quality of Home Spirometry?
Authors:
- Benoit Cuyvers – Product Manager at ArtiQ
- Marko Topalović, Ph.D. – CEO at ArtiQ
Thematic Poster Session A75: REVISITING CURRENT METHODS IN PULMONARY FUNCTION TESTING
Date: Sunday, May 19, 2024
Time: 11:30 a.m. – 1:15 p.m.
Poster Title: The Back-extrapolated Volume Acceptability Criterion for FVC in Clinical Trials for IPF Inappropriately Calls FVCs Unacceptable and Increases Repeat Testing and Screen Failures
Authors:
- Kevin McCarthy – Director, Respiratory Science at Clario
- Phil Lake, Ph.D. – Senior Director, Respiratory Solutions at Clario
- Marc-Aurel Baumle – Director, Respiratory Solutions at Clario
Thematic Poster Session A75: REVISITING CURRENT METHODS IN PULMONARY FUNCTION TESTING
Date: Sunday, May 19, 2024
Time: 11:30 a.m. – 1:15 p.m.
Poster Title: The Impact of Applying the 2019 ATS/ERS Quality Control Criteria for Spirometry on a Large Population Cohort Study Compared With the 2005 Standard
Authors:
- Benoit Cuyvers – Product Manager at ArtiQ
- Sanja Stojanovic, Ph.D. – Dalhousie University, Halifax, NS, Canada
Thematic Poster Session A76: ASSESSING RISKS AND OUTCOMES IN INTERSTITIAL LUNG
Date: Sunday, May 19, 2024
Time: 11:30 a.m. – 1:15 p.m.
Poster Title: The Potential for Baseline Spirometry Variability to Generate Increased Treatment Response in IPF
Authors:
- Kevin McCarthy – Director, Respiratory Science at Clario
- Phil Lake, Ph.D. – Senior Director, Respiratory Solutions at Clario
- Marc-Aurel Baumle – Director, Respiratory Solutions at Clario
Thematic Poster Session C72: CASE REPORTS IN RESPIRATORY STRUCTURE AND FUNCTION
Date: Tuesday, May 21, 2024
Time: 11:30 a.m. – 1:15 p.m.
Poster Title: Submaximal Inhalation Error Detection Can Be Obscured by Operator Technique: Lessons Learned From Clinical Trials
Authors:
- Kevin McCarthy – Director, Respiratory Science at Clario
- Phil Lake, Ph.D. – Senior Director, Respiratory Solutions at Clario
- Marc-Aurel Baumle – Director, Respiratory Solutions at Clario
- Dawn Patterson – Senior Director, Respiratory Solutions at Clario
Presenters
Kevin McCarthy, RPFT
Director, Respiratory Science at Clario
Kevin has worked in the field of lung function testing for 50+ years, with 40 years as the manager of the Pulmonary Function Laboratories at the Cleveland Clinic Health System. He has always been passionate about the quality of pulmonary function measurements and has moved this passion to the clinical trial world where data quality is critical and where these measurements accurately answer questions. Kevin’s research experience includes managing pulmonary function quality control in two NIH-funded registries: patient with severe A1AT deficiency and LAM Registry and the Cleveland Clinic’s NETT study. He has published extensively on pulmonary function testing and is a current member of the ATS PFT Committee and ATS/ERS Task Force to update the standards for Lung Volume testing in which he participated in 2019 to update the standards for Spirometry.
Philip Lake, Ph.D.
Senior Director, Respiratory Solutions at Clario
Phil Lake is a respiratory specialist at Clario who supports global clients. He has held various roles in drug development for 20 years, predominantly focused on respiratory trials. Prior to Clario, Phil worked on several anti-inflammatory agents, dual and triple combination therapy, monoclonal antibody studies, anti-infectives and some of the largest mechanistic studies looking at biomarkers within sputum and biopsy samples at SmithKline Beecham and GlaxoSmithKline. He has experience supporting CROs as a respiratory specialist and as the head of project management. Recently, his concentration has been extensively on rare respiratory diseases, including Cystic Fibrosis and Idiopathic Pulmonary Fibrosis, covering a variety of drug mechanisms and medical devices. Phil was pivotal to some of the first centralized overread studies and is committed to driving improvements in lung function testing.
Marc-Aurel Baumle
Director, Respiratory Solutions at Clario
As a seasoned business developer in the respiratory clinical trial industry, Marc is dedicated to leveraging the latest technology and cutting-edge analysis techniques to deliver unparalleled data quality for our valued customers. With a Master of Science in Industrial Engineering and Management from TU Munich, Marc brings a unique blend of technical expertise and strategic vision to his role at Clario. His passion lies in driving innovation and efficiency within the clinical trial landscape, ensuring that our solutions not only meet but exceed the needs and expectations of our clients. He thrives in dynamic environments where collaboration and forward thinking are key, and is committed to making a meaningful impact in the advancement of respiratory healthcare.
Dawn Patterson
Senior Director, Respiratory Solutions at Clario
After spending 18 years as a respiratory therapist with Taylor Hospital, Dawn Patterson began her 14+ year career with Clario supervising and training clinical specialists in pulmonary function data analysis while designing and monitoring new processes and procedures that would increase the productivity, efficiency, and quality of the respiratory team overall. Today, in addition to providing in-depth strategic direction for both the respiratory and sales teams, Dawn also interacts with and supports customers with informative presentations and seminars on the applications of new products and services.
Benoit Cuyvers
Product Manager at ArtiQ
Benoit is the product manager of the Clinical Research Portfolio of ArtiQ, a company that aims to empower respiratory research & medicine with artificial intelligence. He has been leading the efforts on ArtiQ’s AI-enabled Risk Based Monitoring system (ArtiQ.RBM), from concept to solution. With his background in Bioscience Engineering and his past experience as a digital health expert at Siemens, Benoit is able to apply learnings from other medical and technical fields to the field of AI in respiratory research & medicine.
Julie Maes
Product Manager at ArtiQ
Julie is a product manager for the diagnostic portfolio of ArtiQ, a company that aims to empower respiratory research and medicine with artificial intelligence. She leads efforts to bring AI-supported interpretation of lung function to healthcare practitioners to support accurate and timely diagnosis for patients with lung disease. She collaborates with equipment manufacturers and pharmaceutical companies to support the roll-out of the technology to generate real-world evidence. Julie is currently developing technologies and models to bridge lung function testing in routine clinical practice with clinical research to lower site burden and increase access to clinical trials. With her background in Biomedical Engineering and experience as a product marketer in cardiovascular for 3D planning and printing, Julie applies learnings from various medical fields and innovative technologies to the field of AI in respiratory research and medicine.
Marko Topalović, Ph.D.
CEO at ArtiQ
Marko is the CEO of ArtiQ a company that aims to empower medical professionals with artificial intelligence to accurately and timely diagnose, treat and monitor patients with lung diseases. Formerly, as a postdoctoral researcher in the University Hospital in Leuven (Belgium), Marko worked on inventing algorithms for assessing lung disease. He obtained a Ph.D. degree on the topic “Artificial intelligence for pulmonary function tests” at the KU Leuven. His scientific work has contributed to many peer-reviewed publications and numerous conference presentations. Moreover, he has also received several international awards for his work.
Meet with us at ATS 2024.
Complete this form and we will reach out soon to schedule a time to connect at the event.
If you are a company wishing to collaborate with us, please stop by our booth during the conference to talk with our team.